It is being widely adopted amongst the FSHD community and has proven useful in demonstrating the effectiveness of LNA gapmer antisense oligonucleotides to reduce DUX4 expression in vivo (Lim et al., 2020) and in showing a sarcolemmal repair defect and decreased torque in DUX4-expressing muscle (Bittel et al., 2020). This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.